Literature DB >> 9442063

The human Rh50 glycoprotein gene. Structural organization and associated splicing defect resulting in Rh(null) disease.

C H Huang1.   

Abstract

The Rh (Rhesus) protein family comprises Rh50 glycoprotein and Rh30 polypeptides, which form a complex essential for Rh antigen expression and erythrocyte membrane integrity. This article describes the structural organization of Rh50 gene and identification of its associated splicing defect causing Rhnull disease. The Rh50 gene, which maps at chromosome 6p11-21.1, has an exon/intron structure nearly identical to Rh30 genes, which map at 1p34-36. Of the 10 exons assigned, conservation of size and sequence is confined mainly to the region from exons 2 to 9, suggesting that RH50 and RH30 were formed as two separate genetic loci from a common ancestor via a transchromosomal insertion event. The available information on the structure of RH50 facilitated search for candidate mutations underlying the Rh deficiency syndrome, an autosomal recessive disorder characterized by mild to moderate chronic hemolytic anemia and spherostomatocytosis. In one patient with the Rhnull disease of regulator type, a shortened Rh50 transcript lacking the sequence of exon 7 was detected, while no abnormality was found in transcripts encoding Rh30 polypeptides and Rh-related CD47 glycoprotein. Amplification and sequencing of the genomic region spanning exon 7 revealed a G-->A transition in the invariant GT motif of the donor splice site in both Rh50 alleles. This splicing mutation caused not only a total skipping of exon 7 but also a frameshift and premature chain termination. Thus, the deduced translation product contained 351 instead of 409 amino acids, with an entirely different C-terminal sequence following Thr315. These results identify the donor splicing defect, for the first time, as a loss-of-function mutation at the RH50 locus and pinpoint the importance of the C-terminal region of Rh50 in Rh complex formation via protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9442063     DOI: 10.1074/jbc.273.4.2207

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Molecular genetics and clinical applications for RH.

Authors:  Willy A Flegel
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

2.  Expression of blood group genes by mesenchymal stem cells.

Authors:  Richard Schäfer; Martina Schnaidt; Roland A Klaffschenkel; Georg Siegel; Michael Schüle; Maria Anna Rädlein; Ursula Hermanutz-Klein; Miriam Ayturan; Marine Buadze; Christoph Gassner; Lusine Danielyan; Torsten Kluba; Hinnak Northoff; Willy A Flegel
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

Review 3.  The Rh protein family: gene evolution, membrane biology, and disease association.

Authors:  Cheng-Han Huang; Mao Ye
Journal:  Cell Mol Life Sci       Date:  2009-12-02       Impact factor: 9.261

4.  Detection of fetal RhD gene from maternal blood.

Authors:  Tuba Günel; Ibrahim Kalelioğlu; Hayri Ermiş; Kılıç Aydınlı
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-06-01

Review 5.  Ammonia transport in the kidney by Rhesus glycoproteins.

Authors:  I David Weiner; Jill W Verlander
Journal:  Am J Physiol Renal Physiol       Date:  2014-03-19

6.  Rhmod syndrome: a family study of the translation-initiator mutation in the Rh50 glycoprotein gene.

Authors:  C Huang; G J Cheng; M E Reid; Y Chen
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

Review 7.  Refined views of multi-protein complexes in the erythrocyte membrane.

Authors:  T J Mankelow; T J Satchwell; N M Burton
Journal:  Blood Cells Mol Dis       Date:  2012-03-31       Impact factor: 3.039

8.  Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing.

Authors:  Joseph Hawksworth; Timothy J Satchwell; Marjolein Meinders; Deborah E Daniels; Fiona Regan; Nicole M Thornton; Marieangela C Wilson; Johannes Gg Dobbe; Geert J Streekstra; Kongtana Trakarnsanga; Kate J Heesom; David J Anstee; Jan Frayne; Ashley M Toye
Journal:  EMBO Mol Med       Date:  2018-06       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.